| 08.26 (Tuesday) | 
										
										
											| The Platz Hall Glass Matchmaking Room (#PE17)  | 
											P-1 | 
											14:00 - 15:00 | 
											Technology transfer seminar - Introduction of promising technologies using biological resource  | 
											National Institute of Biological Resources (NIBR) &  Nakdonggang National Institute of Biological Resources (NNBIR) & Honam National Institute of Biological Resources (HNIBR) & National Institute of Ecology (NIE) | 
											K  | 
										
										
											| 14:00 - 14:15 | 
											A patent for skin-improving use with bio-transformation products of plant extracts as active ingredients | 
											National Institute of Biological Resources (NIBR) | 
											Wonjae Ji, Researcher | 
										
										
											| 14:15 - 14:30 | 
											Production of high-purity freshwater Diatom Biosilica for drug delivery applications  | 
											Nakdonggang National Institute of Biological Resources (NNBIR) | 
											Daeryul Kwon, Associate Researcher | 
										
										
											| 14:30 - 14:45 | 
											Development and Commercialization Research of Biomaterials Derived from Coastal Marine Biological Resources  | 
											Honam National Institute of Biological Resources (HNIBR) | 
											JungUp Park, Senior Researcher | 
										
										
										
											| 14:45 - 15:00 | 
											Utilization of Biomimicry Knowledge Information Systems for Promoting the Bioindustry | 
											National Institute of Ecology (NIE) | 
											Seungwoo Sim, Associate Researcher | 
										
										
											| The Platz Hall Seminar Room (2F) | 
											P-2 | 
											13:30 - 15:30 | 
											DIPS Open Innovation Day - Challenges and Tasks for Building K-BIO's Global Collaboration Ecosystem | 
											Korea Institute of Toxicology (KIT) | 
											 | 
										
										
											| 13:30 - 14:30 | 
											K-BIO: Where we are? Where we want to be? And, how do we get there? | 
											AMC Biosciences, Partner of Shimbio | 
											Dr. Cho Ho Seong, BOD member | 
											K  | 
										
										
											| Invited Presentation Market entry procedures for Saudi Arabia and SFDA requirements | 
											All Care Medical Industries | 
											Mr. Sultan Abdullah Al Mansour, Chairman of AllCareGroup for Investment | 
											E  | 
										
										
											| Open Innovation Performance | 
											 | 
											 | 
											K  | 
										
										
											| 14:30 - 15:30 | 
											Supply Technology Presentation | 
											 | 
											 | 
											K  | 
										
										
											| 13:30 - 17:00 | 
											<Large and mid-sized pharmaceutical and bio companies - DIPS companies Partnering> 
											* Pre-matching/ Location will to be confirmed | 
											Korea Institute of Toxicology (KIT) | 
											K  | 
										
										
										
											| 08.27 (Wednesday) | 
										
										
											| The Platz Hall Seminar Room (2F) | 
											P-3 | 
											10:20 - 12:30 | 
											Current Landscape and Future Prospects of the Exosome Industry | 
											Extracellular Vesicles Industry Association (EVIA) | 
											K  | 
										
										
											| 10:20 - 10:40 |     
											Exosome Technology in Aesthetics and Regenerative Medicine: Current Landscape, Challenges, and Future Prospects | 
											ExoCoBio Inc. | 
											Byong Seung Cho, CEO/CTO | 
										
										
											| 10:40 - 11:00 |    
											Precision EV Isolation: Accelerating Therapeutic Breakthroughs with LabSpinner Technologies | 
											LabSpinner Inc. | 
											Kyusang Lee, CEO | 
										
										
											| 11:00 - 11:20 |    
											Exosome Innovation and Clinical Translation: Unlocking New Therapeutic Possibilities | 
											S&E bio Co., Ltd. | 
											Eun Hee Kim, CTO | 
										
										
											| 11:20 - 11:40 |    
											EV Cargo Control via Preconditioning: Enhancing Therapeutic Potential | 
											Brexogen Inc. | 
											SeungtTaek Oh, EVP | 
										
										
											| 11:40 - 12:00 |    
											Nonclinical and Clinical trial of First-in-class anti-inflammatory exosome therapeutics | 
											ILIAS Biologics Inc. | 
											Chulhee Choi, CEO | 
										
										
											| 12:00 - 12:30 |    
											<Panel Discussion: Current Landscape and Future Prospects of the Exosome Industry>  | 
											
											Panel Moderator: Shingyu Bae (Mdimune) 
Panels: Byong Seung Cho (ExoCoBio Inc.), Kyusang Lee (LabSpinner Inc.), Eun Hee Kim (S&E bio Co., Ltd.), Oh, SeungtTaek (Brexogen Inc.), Chulhee Choi (ILIAS Biologics Inc.)
 | 
										
										
											| P-4 | 
											13:00 - 14:30 | 
											Strengthening Biopharmaceutical Supply Chains: Strategies for Raw Material Localization | 
											Korea Biomedicine Industry Association (KoBIA) | 
											K  | 
										
										
										| 13:00 - 13:10 |  
											Part 1 Policies to Support the Development and Commercialization of Domestic Raw and Auxiliary Materials | 
										
										
										| 13:00 - 13:10 |  
											Biopharmaceutical Raw Materials Commercialization Support Project | 
											Korea Conformity Laboratories (KCL) | 
											Sung Min You, Head of Center | 
										
										13:10 - 13:50 |  
											Part 2 Case Studies on the Commercialization of Domestic Raw and Auxiliary Materials | 
										
										
										| 13:10 - 13:30 |  
											Successful cases of Bio-consumbables Commercialization: Cell Culture Media & Purification Resin | 
											Amicogen | 
											Su-Lim Choi, Head of R&D | 
										
										
										| 13:30 - 13:50 | 
											Startup's Challenge to Localize Bioprocess | 
											UMTR Co.,Ltd. | 
											Sungryul Park, CEO | 
										
										
											| 13:50 - 14:30 | 
											Part 3 <Panel Discussion: Key Challenges and Strategies for Strengthening the Competitiveness of Domestic Raw and Auxiliary Materials>  | 
											Panel Moderator: Youngbin Baek (Inha University) 
Panels: Sung Min You (Korea Conformity Laboratories), Su-Lim Choi (Amicogen), Sungryul Park (UMTR), Yoon Hee-Jeong (Korea Institute of S&T Evaluation and Planning), Kim Hyung-cheol (Korea Planning & Evaluation Institute of Industrial Technology) | 
										
										
											| P-5 | 
											15:30 - 17:00 | 
											Patient-Centered Innovation Strategies to Conquer Intractable Diseases | 
											Korea Biomedicine Industry Association (KoBIA) & K-Health MIRAE Initiative (Korean ARPA-H Project) & Hit Media	 Panel Moderator: Yoonbin Kim, PM of K-Health MIRAE Initiative (Korean ARPA-H Project) | 
											K  | 
										
										
											| 15:30 - 15:55 | 
											Patient Engagement in Medical Product Development and Regulatory Decision-making | 
											Sungkyunkwan University | 
											Mihai Park, Research Professor | 
										
										
											| 15:55 - 16:15 | 
											Innovative, Patient-Tailored Strategy for Rare Disease Drug Development HEART and BEACON | 
											K-Health MIRAE Initiative (Korean ARPA-H Project) | 
											Misun Park, PM | 
										
										
											| 16:15 - 16:35 | 
											Implication of personalized cancer vaccine (PCV) R&D project based on the cutting-edge technology of Korea. | 
											Aston Sci. Inc. | 
											Jung, Hun, CEO | 
										
										
											| 16:35 - 16:55 | 
											Expected Benefits of Proactive Early Cancer Detection Enabled by Enhanced Patient Accessibility and Convenience | 
											IMBdx | 
											Tae-You Kim, CEO | 
										
										
										
										
											| 08.28 (Thursday)	 | 
										
										
											| The Platz Hall Seminar Room (2F) | 
											P-6 | 
											10:00 - 12:30 | 
											DIPS Global IR Day | 
											Korea Institute of Toxicology (KIT) | 
											 | 
										
										
											| 10:00 - 10:15 | 
											Topic Presentation Investment Attraction Strategy for K Bio Companies in a Time of Transition | 
											LSK Investment | 
											Myungkee Kim, CEO | 
											K  | 
										
										
											| 10:15 - 10:30 | 
											US Biohealth Investment Trends and Implications | 
											Shimbio | 
											Kwangryong Yoo, CEO | 
											K  | 
										
										
											| 10:30 - 10:45 | 
											Trends in bio investment in Europe, including the UK, and Korean companies' entry strategies	 | 
											SD&k	 | 
											Minsik Gong, CEO | 
											K  | 
										
										
											| 10:45 - 11:00 | 
											Saudi’s Strategic Investment Proposal for K Bio companies in Partnership with All Care group	 | 
											AllCare Group	 | 
											Mr. Sultan Abdullah Al Mansour, Chairman of AllCareGroup for Investment | 
											E  | 
										
										
											| 11:00 - 11:50 | 
											IR of DIPS companies | 
											 | 
											 | 
											K  | 
										
	
										
											| 10:00 - 12:30 | 
											<Partnering with Global VCs and DIPS companies> 
* Pre-matching/ Location will to be confirmed | 
											Korea Institute of Toxicology (KIT) | 
											K  | 
										
										
												| P-7 | 
												13:40 - 15:30 | 
												Pharmaceutical Industry Outlook in Ethiopia, Peru, and Uzbekistan – Policy Environment, Market Access, and Investment Incentives | 
												United Nations Industrial Development Organization (UNIDO) | 
												E  | 
											
											
											
												| 13:50 - 14:20 | 
												Pharmaceutical Industry Outlook in Ethiopia – Policy Environment, Market Access, and Investment Incentives | 
												Ethiopian Pharmaceutical Supply Agency (EPSS) - Ethiopia | 
												Abdulkedir Gelgelo, Director General | 
											
											
												| 14:20 - 14:50 | 
												Pharmaceutical Industry Outlook in Peru – Policy Environment, Market Access, and Investment Incentives | 
												Lima Chamber of Commerce (CCL) | 
												Sandro Stapleton, Director of the Health Committee | 
											
											
												| 14:50 - 15:30 | 
												Pharmaceutical Industry Outlook in Uzbekistan – Policy Environment, Market Access, and Investment Incentives | 
												Embassy of the Republic of Uzbekistan in the Republic of Korea | 
												Rukhullo Zikrillaev, Counsellor on Trade and Economic Affairs |